{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Neoplasms&page=25",
    "query": {
      "condition": "Soft Tissue Neoplasms",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 2035,
    "total_pages": 204,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Neoplasms&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Neoplasms&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T21:28:56.747Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03345485",
      "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Soft Tissue Sarcoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Tinostamustine 60mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 60mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 80min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-11-08",
      "completion_date": "2023-03-29",
      "has_results": true,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345485"
    },
    {
      "nct_id": "NCT03190174",
      "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "PEComa",
        "Epithelioid Sarcoma",
        "Desmoid Tumor",
        "Chordoma",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Colorectal Cancer",
        "MTOR Activating Mutation"
      ],
      "interventions": [
        {
          "name": "Nab-Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sarcoma Oncology Research Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-08-24",
      "completion_date": "2021-12-02",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190174"
    },
    {
      "nct_id": "NCT00003723",
      "title": "S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Mesothelioma"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "1999-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 84,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003723"
    },
    {
      "nct_id": "NCT02228174",
      "title": "Sonography Guided Transcervical Ablation of Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menorrhagia"
      ],
      "interventions": [
        {
          "name": "Intrauterine Ultrasound-Guided Radiofreq. Ablation System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Gynesonics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 50 Years · Female only"
      },
      "enrollment_count": 147,
      "start_date": "2014-10",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228174"
    },
    {
      "nct_id": "NCT00064324",
      "title": "Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Adult Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "perifosine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2003-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064324"
    },
    {
      "nct_id": "NCT02192346",
      "title": "α-TEA in Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Carcinoma",
        "Metastatic Sarcoma",
        "Metastatic Lymphoma"
      ],
      "interventions": [
        {
          "name": "2.4 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "4.8 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "8.0 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "9.6 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "12 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "16.8 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "19.2 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "22.3 mg/kg α-TEA",
          "type": "DRUG"
        },
        {
          "name": "26.8 mg/kg α-TEA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2014-08-04",
      "completion_date": "2018-05-08",
      "has_results": false,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 5,
      "location_summary": "Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more",
      "locations": [
        {
          "city": "Clackamas",
          "state": "Oregon"
        },
        {
          "city": "Newberg",
          "state": "Oregon"
        },
        {
          "city": "Oregon City",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02192346"
    },
    {
      "nct_id": "NCT01742286",
      "title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALK-activated Tumors"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 83,
      "start_date": "2013-08-28",
      "completion_date": "2019-04-26",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742286"
    },
    {
      "nct_id": "NCT04311073",
      "title": "Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibroid Uterus",
        "Abnormal Uterine Bleeding",
        "Myoma;Uterus"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Virginia Medical School",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2020-06-20",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04311073"
    },
    {
      "nct_id": "NCT04837677",
      "title": "A Study of PRT1419 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Melanoma",
        "Lung Cancer",
        "Breast Cancer",
        "Esophageal Cancer",
        "Cervical Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "PRT1419",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-08-11",
      "completion_date": "2023-02-06",
      "has_results": false,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837677"
    },
    {
      "nct_id": "NCT00822848",
      "title": "Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "hypofractionated radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "15 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2009-02",
      "completion_date": "2013-04-30",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-11-17T21:28:56.747Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822848"
    }
  ]
}